NAT1 (N-Acetyltransferase 1) Drug Discovery Landscape & Assay Solutions
- By admin
- 18 Aug 2026
- Comments
Combining insights from metabolic enzyme targeting, pharmacogenomics, and oncology biomarker development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NAT1 drug discovery, including wild-type and clinically relevant polymorphic variants (R64W, V149I, R187Stop).
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | NAT1 Recombinant Protein (WT & Polymorphic Variants) – High purity (>95%), Endotoxin <1EU/ug, Sequence Verified by mass spec and theoretical MW. | View NAT1 Products |
| Gene Delivery | NAT1 Promise-ORF / Lentivirus – Full-length ORF for stable cell lines. | View NAT1 Products |
| Benchmark Ab | Anti-NAT1 Control Antibody / Research Grade – Recombinant positive control for western blot and ELISA. | View NAT1 Products |
| Validator | NAT1 siRNA Set – For knockdown verification and functional assays. | View NAT1 Products |
| Related Target A | NAT2 – Critical homolog for isoform selectivity profiling and counter-screening. | View NAT2 Products |
| Related Target B | ESR1 (Estrogen Receptor alpha) – Highly co-expressed in HR+ breast cancer, key for combination therapy. | View ESR1 Products |
| Related Target C | TPMT (Thiopurine S-Methyltransferase) – Complementary metabolic pathway in drug detoxification and personalized medicine. | View TPMT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| NAT1/NAT2 Isoform Selectivity | Human NAT1 & NAT2 ortholog proteins available with >95% purity; distinct epitope regions mapped. |
| Polymorphic Variant Screening | Clinically relevant mutants (R64W, V149I, R187Stop) sequence-verified by mass spec; correspond to NAT117, NAT15, NAT1*11 alleles. |
| Enzymatic Activity Preservation | Optimized expression systems ensuring proper folding and high-specific activity for acetyltransferase assays. |
| Lack of Validated Reagents | High purity proteins, specific siRNA, and recombinant antibodies included for reliable specificity checks. |
Live NAT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for NAT1 is evolving from traditional detoxification inhibition toward precision oncology and pharmacogenomics. Originally recognized for its role in phase II xenobiotic metabolism, NAT1 is now a validated biomarker and therapeutic target for estrogen receptor-positive (ER+) breast cancer, where small molecule inhibitors and targeted protein degraders (PROTACs) are under active development. Simultaneously, NAT1 polymorphisms (e.g., slow acetylator alleles NAT1*5, *11, *17) critically impact drug efficacy and toxicity, driving demand for pharmacogenomic assays that discriminate between rapid and slow acetylator phenotypes. The next wave of R&D includes highly selective inhibitors that avoid NAT2 cross-reactivity to minimize drug-drug interactions, combination strategies with endocrine therapies (e.g., tamoxifen), and prodrug activation approaches enhanced by NAT1 activity profiling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic spin-offs, specialized biotech, academic consortia | ER+ Breast Cancer, Solid Tumors (prodrug enhancement) | Selectivity Assay requiring high-purity NAT1 vs NAT2 proteins |
| Targeted Protein Degraders (PROTACs) | Emerging oncology biotechs | Refractory Breast Cancers | Binding Assays requiring sequence-verified intracellular domains |
| Diagnostic Antibodies | Leading IVD companies | Companion Diagnostics, IHC | High-affinity validation requiring recombinant positive controls |
| Pharmacogenomic Assays | Diagnostic companies | Personalized Medicine (slow/fast acetylator status) | Polymorphic variant panel needing R64W, V149I, R187Stop mutants |
| Prodrug Optimization | Oncology-focused pharma | Colorectal Cancer, Infectious Disease | Metabolic stability assay needing active recombinant enzyme |
Key Polymorphic Variants & Pharmacogenomic Considerations
NAT1 genetic polymorphisms significantly alter enzymatic activity and clinical outcomes. Three well-characterized variants are highlighted:
- NAT1*17 (rs563, R64W): Slow acetylator with defective enzyme activity; associated with increased toxicity of aromatic amine drugs.
- NAT1*5 (rs55641436, V149I): Reduced catalytic efficiency; common in various populations.
- NAT1*11 (VAR_004607): Altered N-acetylation capacity; impacts prodrug metabolism.
These variants require sequence-verified recombinant proteins for accurate pharmacogenomic assay development and personalized therapeutic strategies.